Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting
28 avr. 2023 08h15 HE
|
Processa Pharmaceuticals, Inc.
PCS12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis PatientsPCS12852 Improved Both Gastroparesis Symptom Scores and Gastric Emptying Rate HANOVER, MD, April ...